El efecto de la triple hélice en los resultados de innovación

La innovación está relacionada con el crecimiento de las economías y de las empresas, y en un entorno cambiante como el actual, se presenta como una herramienta fundamental para conseguir ventajas competitivas. Esta investigación tiene por objetivo analizar la relación existente entre la capacidad de innovación de las empresas y la obtención de información de las mismas a través de la cooperación con competidores, proveedores, Universidades y otras instituciones públicas (Triple Hélice). En primer lugar se desarrolla una revisión bibliográfica de los conceptos relacionados para posteriormente, a través del método de ecuaciones estructurales, dar respuesta y aceptar la hipótesis propuesta que pone de manifiesto la relación existente entre los resultados de innovación de las empresas y la información obtenida de la Triple Hélice. La investigación se realiza con una muestra de empresas españolas, encuestadas por el Instituto Nacional de Estadística (INE), durante los años 2008-2010.

Perceptions of the usefulness of external support to immunization coverage in Guinea-Bissau: a Delphi analysis of the GAVI-Alliance cash-based support

INTRODUCTION: Although many countries have improved vaccination coverage in recent years, some, including Guinea-Bissau, failed to meet expected targets. This paper tries to understand the main barriers to better vaccination coverage in the context of the GAVI-Alliance (The Global Alliance for Vaccines and Immunisation) cash-based support provided to Guinea-Bissau. METHODS: The analysis is based on a document analysis and a three round Delphi study with a final consensus meeting. RESULTS: Consensus attributed about 25% of the failure to perform better to implementation problems; and about 10% to governance and also 10% to scarce resources. The qualitative analysis validates the importance of implementation issues and upgraded the relevance of the human resources crisis as an important drawback. The recommendations were balanced in their upstream-downstream focus but were blind to health information issues and logistical difficulties. CONCLUSIONS: It is commendable that such a fragile state, with all sorts of barriers, manages to sustain a slow steady growth of its vaccination coverage. Not reaching the targets set reflects the inappropriateness of those targets rather than a lack of commitment of the health workforce. In the unstable context of countries such as Guinea-Bissau, the predictability of the funds from global health initiatives like the GAVI-Alliance seem to make all the difference in achieving small consistent health gains even in the presence of other major bottlenecks.

Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer

Triple therapy is accepted as the treatment of choice for H. pylori eradication. In industrialized countries, a proton pump inhibitor plus clarithromycin and amoxicillin or nitroimidazole have shown the best results. Our aims were: 1. To study the eradication rate of the association of a proton pump inhibitor plus tinidazole and clarithromycin on H. pylori infection in our population. 2. To determine if previous treatments, gender, age, tobacco, alcohol use, and non-steroidal anti-inflammatory drugs (NSAIDs) change the response to therapy. METHODS: Two hundred patients with peptic ulcer (upper endoscopy) and H. pylori infection (histology and rapid urease test - RUT) were included. A proton pump inhibitor (lansoprazole 30 mg or omeprazole 20 mg), tinidazole 500 mg, and clarithromycin 250 mg were dispensed twice a day for a seven-day period. Eradication was assessed after 10 to 12 weeks of treatment through histology and RUT. RESULTS: The eradication rate of H. pylori per protocol was 65% (128/196 patients). This rate was 53% for previously treated patients, rising to 76% for not previously treated patients, with a statistical difference p<0.01. No significant difference was observed regarding sex, tobacco use, alcohol consumption, and NSAID use, but for elderly patients the difference was p = 0.05. Adherence to treatment was good, and side effects were mild. CONCLUSIONS: A proton pump inhibitor, tinidazole, and clarithromycin bid for seven days resulted in H. pylori eradication in 65% of the patients. Previous treatments were the main cause of treatment failure.

Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer

PURPOSE: To determine the eradication rate of an ultra-short treatment schedule for Helicobacter pylori infection in a population with peptic ulcers, using omeprazole, secnidazole, and azithromycin in a once-daily dose for 3 days. METHODS: Thirty patients with peptic ulcer diagnosed by upper endoscopy and for Helicobacter pylori infection by rapid urease test and histologic examination received omeprazole 40 mg, secnidazole 1000 mg, and azithromycin 500 mg, administered once daily for 3 days. A follow-up exam was performed 12 weeks after the end of the treatment. Patients who were negative for Helicobacter pylori infection by rapid urease test and histologic examination were considered cured. RESULTS: Patients were predominantly female, and the mean age was 50 years. Duodenal peptic ulcer was found in 73% of the patients. Eradication was achieved in 9 of the 28 (32%) patients as determined from the follow-up endoscopic exam. The eradication rate by intention to treat was 30%. Side effects were present in 3% of the patients, and compliance to treatment was total. CONCLUSIONS: In spite of the low rate of side effects and good compliance, the eradication index was low. A possible drawback of this therapy is that it reduces the efficacy of macrolide and nitroimidazole compounds in subsequent treatments.

Limnaea peregrina Clessin, 1882, Synonym of Lymnaea columella Say, 1817 (Gastropoda: Lymnaeidae)

A description is given of the shell, radula, renal region, reproductive system and egg capsules of topotypic specimens of limnaea peregrina Clessin, 1882. This investigation intends contributing to define the specific identity of that nominal species. A close anatomical comparison with Lymnaea columella Say, 1817 from Michigan, USA, shows that both forms are indistinguishable, giving support to previous inferences from some authors. Data on egg hatching are presented.

The role of triple infection with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) type-1 on CD4+ lymphocyte levels in the highly HIV infected population of North-Central Nigeria

We set out to determine the seroprevalence of hepatitis B and C among human immunodeficiency virus type-1 (HIV-1) infected individuals in North-Central Nigeria to define the influence of these infections on CD4+ lymphocytes cells among our patients as access to antiretroviral therapy improves across the Nigerian nation. The CD4+ values of 180 confirmed HIV-1 infected individuals were enumerated using a superior fluorescence-activated cell sorter system. These patients were tested for the presence of hepatitis B surface antigen and anti-hepatitis C virus (HCV) using third generation enzyme-linked immunosorbent assays. Fifty (27.8%) patients had active hepatitis B virus (HBV) infection while 33 (18.3%) tested positive for anti-HCV antibody. Of these infections, 110 (61.1%), 37 (20.6%), and 20 (11.1%) had HIV only, HBV/HIV-only, and HCV/HIV-only respectively. A HBV/HCV/HIV coinfection prevalence of 7.2% (13 patients) was recorded. Patients coinfected with HIV/HBV/HCV appeared to have lower CD4+ counts (mean = 107 cells/µl; AIDS defining) when compared to HBV/HIV-only (mean = 377 cells/µl), HCV/HIV-only (mean = 373 cells/µl) and patients with mono HIV infection (mean = 478 cells/µl). Coinfection with HBV or HCV is relatively common among HIV-infected patients in Nigeria and should be a big consideration in the initiation and choice of therapy.

Health-Related Quality of Life in patients with hepatitis C in double and triple therapy

Abstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.

Biologia, comportamento social e alocação sexual de Digelasinus diversipes (Kirby, 1882) (Hymenoptera, Argidae)

São apresentados os resultados de um estudo de dois anos sobre o Symphyta neotropical Digelasinus diversipes. Esta espécie é univoltina e comum na Estação Ecológica Jataí, uma reserva de Cerrado no Estado de São Paulo. As larvas alimentam-se gregariamente em Eugenia glazioviana (Myrtaceae) de novembro a abril. Associações entre grupos de alimentação foram freqüentes. Após o período de alimentação, as larvas congregam-se e comunalmente constróem uma massa de casulos (105 casulos ± 60DP; n = 25) aderida ao tronco da planta hospedeira, permanecendo em diapausa como prepupas até o início da estação chuvosa, em outubro. O pico populacional foi observado em dezembro, quando 62% (n = 2.967) dos adultos emergiram. Em condições experimentais, foram observadas emergências das 6:30 às 15:00 h, mas 73,5% (n = 223) dos adultos emergiram entre 9:00 e 12:00 h. Não foi observado, durante a emergência, sequenciamento sexual, mas em um agregado de casulos os machos podem emergir de 20 a 40 dias antes das fêmeas. Após a emergência os machos podem (1) dispersar-se (no início e final do período de emergência; outubro e novembro, janeiro e fevereiro, respectivamente) ou (2) permanecer sobre ou próximo ao agregado de casulos e copular com as fêmeas recém-emergidas (durante o pico de emergência, em dezembro). As cópulas duraram 4,28 minutos (± 3,4DP; n = 28). Ao longo do dia, os machos podem copular com diferentes fêmeas (1-8; n = 5); contudo, as fêmeas copularam apenas uma vez. Em média, as fêmeas emergem com 76 (± 21DP; n = 19) ovos maduros e todos eles são ovipositados de uma só vez sob uma única folha da planta hospedeira. A guarda dos ovos pelas fêmeas durou apenas 2 dias (n = 12) dos 30 necessários para sua incubação. O repertório de comportamentos da fêmea contra potenciais inimigos foi menor do que o observado em outras espécies de Symphyta. Aparentemente, a fêmea induz um necrosamento do tecido foliar que cobre os ovos. Isto formaria uma proteção rígida para os ovos durante sua incubação. Em D. diversipes, adultos de ambos os sexos não se alimentaram (condição controlada) e tiveram vida curta (5,2 dias ± 1,7DP; mínimo 1, máximo 11; n = 179). A razão sexual média foi 2,83 (± 0,014EP) em favor de fêmeas. Os principais fatores de mortalidade foram falhas no desenvolvimento, falta de alimento devido à intensa herbivoria e ataque de parasitóides. Parasitóides criados, Lymeon dieloceri (Costa Lima, 1937) (Ichneumonidae), Conura (Spilochalcis) sp. (Chalcididae) e Perilampus sp. (Perilampidae).

The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials

Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitroand in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pyloritreatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07) and 68.33% (95%CI: 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI: 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20) and 27.17% (95%CI: 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.